Biosimilars, Drugs and Marketing - Drug Discovery Digest

CVS launches new venture in biosimilar drug experiment

BioPharma Drive: Drug Pricing

AUGUST 24, 2023

The subsidiary, called Cordavis, will work directly with manufacturers to market or co-produce low-cost biologic drugs, starting with Novartis’ Humira copy.

Biosimilars

Biosimilars Drugs Marketing

The impact of biosimilars on biologic drug life cycle management

Drug Patent Watch

MARCH 16, 2025

The Biosimilar Revolution: How It's Changing the Game for Biologic Drug Manufacturers As the pharmaceutical industry continues to evolve, one trend is gaining significant attention: the rise of biosimilars. In this article, we'll explore the impact of biosimilars on biologic drug life cycle management.

Blue Shield of California sidesteps PBMs with new Humira biosimilar deal

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the drug and biologic copycats.

Biosimilars

Biosimilars Marketing Drugs

Handling Drug Patent Invalidity Claims

Drug Patent Watch

DECEMBER 8, 2024

The pharmaceutical industry is heavily reliant on patents to protect intellectual property and maintain market exclusivity. However, with the increasing competition from generic and biosimilar manufacturers, patent invalidity claims have become a significant challenge for pharmaceutical companies.

The Competitive Edge of Biosimilars

DrugBank

SEPTEMBER 26, 2024

Biosimilars Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.

Betting Big on Biosimilars: How Evolving Market Dynamics Will Impact Patient Access

Drug Channels

JANUARY 28, 2022

Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. It's a moderated discussion with payers on how the changing market might impact their management strategies in immunology.

Biosimilars

Biosimilars Marketing Drugs

Alvotech deal could heighten biosimilar pressure on Humira

BioPharma Drive: Drug Pricing

APRIL 19, 2024

The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.

Biosimilars

Biosimilars Marketing Drugs

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Licensing

Licensing Licensing Drugs Clinical Trials

Analyzing the impact of biosimilars on biologic drug manufacturing technologies

Drug Patent Watch

DECEMBER 10, 2024

Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies.

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

Drug Channels

OCTOBER 3, 2023

Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.

Four Crucial Questions about the Humira Biosimilar Price War

Drug Channels

JULY 18, 2023

The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Pharmacy Marketing Drugs

The Biosimilar Boom and the Coming Humira Price War (Video)

Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. That’s when Humira, the best-selling drug in the U.S., will face multiple biosimilar competitors. d/b/a Drug Channels Institute.

Biosimilars

Biosimilars Marketing Drugs Production

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha

Drug Channels

FEBRUARY 7, 2023

As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Our crazy drug channel led Amgen to launch both a high-list/high-rebate and a low-list/low-rebate version of the drug. d/b/a Drug Channels Institute. This Feed is for personal non-commercial use only.

Biosimilars

Biosimilars Drugs Production Marketing

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

Drug Channels

OCTOBER 14, 2022

Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. d/b/a Drug Channels Institute. d/b/a Drug Channels Institute. Read on for Steve’s insights.

Drug Channels Update: Buy-and-Bill Market Trends (NEW Live Video Webinar)

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. d/b/a Drug Channels Institute. to 1:30 p.m.

Marketing

Marketing Biosimilars Drugs Hospitals

Drug Channels News Roundup, July 2022: CVS vs. NACDS, ICER Impact, Biosimilar Boom, Deductible Doubts, and Alto Pharmacy (and me)

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. d/b/a Drug Channels Institute. P.S. Join my nearly 30,000 (!) to 1:30 p.m.

Biosimilars

Biosimilars Pharmacy Drugs Marketing

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies

Drug Channels

SEPTEMBER 13, 2022

Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

The Booming Biosimilar Market of 2020

Drug Channels

OCTOBER 6, 2020

The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. As I predicted last year, newer biosimilars are being adopted quickly, and their prices are declining rapidly.

Biosimilars

Biosimilars Marketing Regulations FDA

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies (rerun)

Drug Channels

DECEMBER 12, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. d/b/a Drug Channels Institute. 117-169).

Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss

BioPharma Drive: Drug Pricing

OCTOBER 15, 2024

Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.

Biosimilars

Biosimilars Production Marketing Drugs

The Booming Biosimilar Market of 2020 (rerun)

Drug Channels

DECEMBER 17, 2020

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021. Drug pricing perceptions always seem to lag reality. Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began. The biosimilar market is finally beginning to fulfill its promise.

Biosimilars

Biosimilars Marketing Regulations FDA

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars (rerun)

Drug Channels

DECEMBER 11, 2023

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2024 live video webinar. CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars

Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars

Biosimilars Pharmacy Drugs Marketing

Biosimilar makers split strategies in bid to take on top-selling Humira

BioPharma Drive: Drug Pricing

JULY 26, 2023

In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

Biosimilars

Biosimilars Marketing Drugs

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha (rerun)

Drug Channels

MARCH 30, 2023

So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version. As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. d/b/a Drug Channels Institute. In February, AbbVie stated that U.S.

Biosimilars

Biosimilars Pharmacy Drugs Production

FDA Tells Congress What It Wants, What it Really Really Wants (it really really really wants a zigazig-ah)

FDA Law Blog: Biosimilars

APRIL 2, 2024

Perhaps unsurprisingly given the extraordinary focus on drug pricing in the last decade, generic competition—FDA’s only real way to have an effect on drug pricing—tops this year’s list. In the second category—limiting blockades to marketing—are efforts to limit blocking exclusivities and induced infringement liability.

FDA

FDA Biosimilars Production Marketing

Teva and Bioeq Announce Commercial Partnership for Biosimilar

The Pharma Data

JUNE 30, 2021

Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis ® ) in Europe, Canada, Israel and global markets. Bioeq has in-licensed the exclusive global commercialization rights to FYB201 from the German biosimilar developer Formycon AG.

Decades Later, Congress Continues Debating the Preserve Access to Affordable Generics (and Biosimilars) Act; But will the Recent Jarkesy SCOTUS Decision Finally Put an End to the Insanity?

FDA Law Blog: Biosimilars

AUGUST 29, 2024

Shumsky — As readers of this blog know ( see, e.g. , here ), the Affordable Generics (and Biosimilars) Act has been floating around in Congress for the better part of two decades. Karst & Michael D. Supreme Court declined to hold, in FTC v. Actavis, Inc. ,

Drug Channel Implications of the Inflation Reduction Act (NEW Live Video Webinar)

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Pharmacy

Pharmacy Biosimilars Drugs Marketing

When Payers Become Producers: Inside the PBM Private-Labeling Trend

Drug Channels

AUGUST 16, 2024

Today’s guest post comes from Benjamin Hinton II, Senior Market Access Solutions Analyst at MMIT. Benjamin reviews the growing trend of PBMs vertically integrating into the production of biosimilars. The findings shed light on payers' view of biosimilar conpetition, contracting challenges, and other issues.

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

Drug Channels

SEPTEMBER 4, 2024

The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announced that it that will follow CVS Health’s CVS Caremark business and remove Humira from its largest commercial formulary in favor of multiple biosimilars. All rights reserved.

Biosimilars

Biosimilars Production Marketing Drugs

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT.

Drug Channels Outlook 2024 (NEW Live Video Webinar)

Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.

Pharmacy

Pharmacy Drugs Biosimilars Marketing

FDA approves first interchangeable biosimilar insulin product for treatment of diabetes

The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Biosimilars marketed in the U.S. for the treatment of diabetes.

Biosimilars

Biosimilars Production FDA Approval FDA

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup (rerun)

Drug Channels

APRIL 3, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The 2024 formularies described below should boost biosimilar adoption. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars

Biosimilars Pharmacy Drugs Production

Déjà Vu: OPDP Again Targets Provider Branded Website of Accelerated Approval Drug in Second Untitled Letter of 2025

FDA Law Blog: Biosimilars

APRIL 13, 2025

By Sarah Wicks & Dara Katcher Levy FDAs Office of Prescription Drug Promotion (OPDP) issued its second Untitled Letter of 2025 to Taiho Oncology (Taiho) for a healthcare provider branded website for its drug LYTGOBI (futibatinib). Both cases involve oncology drugs granted accelerated approval. What Happened?

Drugs

Drugs FDA Trials Treatment

Get Your Certificate in Generic and Branded Drug Lifecycle Management

Drug Patent Watch

JUNE 3, 2021

Get Your Certificate Today By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay…. The post Get Your Certificate in Generic and Branded Drug Lifecycle Management appeared first on DrugPatentWatch - Make Better Decisions.

Biosimilars

Biosimilars Drugs Marketing

Investment Trends in Pharmaceutical Research

DrugBank

AUGUST 9, 2024

The average cost of bringing a new drug to market is about $2.6 Moreover, the probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved. Pharmaceutical Market Analysis The global pharmaceutical market revenue in 2024 is projected to be 1.15

Pharmaceuticals

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials

Informa Connect’s PBM Contracting Summit

Drug Channels

OCTOBER 7, 2024

What are the market impacts of innovative models such as Mark Cuban's Cost Plus Drugs and Amazon's pharmacy model? What is the best solution to navigate the challenges of the 340B drug pricing program and PBM contracting? What market dynamics and barriers are impacting pricing and demand? And much more !

Pharmacy

Drug Channels Outlook 2022 (NEW Live Video Webinar)

Drug Channels

NOVEMBER 15, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. d/b/a Drug Channels Institute. Broadcast live on December 17, 2021. to 1:30 p.m.

Specialty Pharmacies

Specialty Pharmacies Biosimilars Drugs Pharmacy

FDA Releases Draft Guidance on Essential Drug Delivery Outputs

FDA Law Blog: Biosimilars

JULY 23, 2024

Lenz, Principal Medical Device Regulation Expert — For several years, FDA has requested that sponsors of drug or biologic led combination products identify essential performance requirements (EPRs) related to the device constituent in their applications. By Adrienne R. does not use this term.

FDA

FDA Drugs Pharmacokinetics Production

Would I FIE to You? FDA’s First Interchangeable Exclusivity Determination Results in Expiration

FDA Law Blog: Biosimilars

JANUARY 11, 2024

The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer.

Biosimilars

Biosimilars FDA Production Marketing

Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China

The Pharma Data

NOVEMBER 23, 2020

have partnered with Yangtze River Pharmaceutical Group, a leading Chinese pharmaceutical company, to form an exclusive strategic partnership for the commercialization of eight biosimilar medicines in China. Ltd are gaining an extremely valuable access to Yangtze River Pharmaceutical’s strong brand reputation and market experience in China.

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

The Pharma Data

MAY 15, 2023

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced a multi-year partnership with Just – Evotec Biologics, the Seattle-based subsidiary of Evotec SE.

CVS launches new venture in biosimilar drug experiment

The impact of biosimilars on biologic drug life cycle management

Trending Sources

Blue Shield of California sidesteps PBMs with new Humira biosimilar deal

Handling Drug Patent Invalidity Claims

The Competitive Edge of Biosimilars

Betting Big on Biosimilars: How Evolving Market Dynamics Will Impact Patient Access

Alvotech deal could heighten biosimilar pressure on Humira

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Analyzing the impact of biosimilars on biologic drug manufacturing technologies

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

Four Crucial Questions about the Humira Biosimilar Price War

The Biosimilar Boom and the Coming Humira Price War (Video)

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

Drug Channels Update: Buy-and-Bill Market Trends (NEW Live Video Webinar)

Drug Channels News Roundup, July 2022: CVS vs. NACDS, ICER Impact, Biosimilar Boom, Deductible Doubts, and Alto Pharmacy (and me)

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies

The Booming Biosimilar Market of 2020

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies (rerun)

Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss

The Booming Biosimilar Market of 2020 (rerun)

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars (rerun)

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars

Biosimilar makers split strategies in bid to take on top-selling Humira

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha (rerun)

FDA Tells Congress What It Wants, What it Really Really Wants (it really really really wants a zigazig-ah)

Teva and Bioeq Announce Commercial Partnership for Biosimilar

Decades Later, Congress Continues Debating the Preserve Access to Affordable Generics (and Biosimilars) Act; But will the Recent Jarkesy SCOTUS Decision Finally Put an End to the Insanity?

Drug Channel Implications of the Inflation Reduction Act (NEW Live Video Webinar)

When Payers Become Producers: Inside the PBM Private-Labeling Trend

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

Drug Channels Outlook 2024 (NEW Live Video Webinar)

FDA approves first interchangeable biosimilar insulin product for treatment of diabetes

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup (rerun)

Déjà Vu: OPDP Again Targets Provider Branded Website of Accelerated Approval Drug in Second Untitled Letter of 2025

Get Your Certificate in Generic and Branded Drug Lifecycle Management

Investment Trends in Pharmaceutical Research

Informa Connect’s PBM Contracting Summit

Drug Channels Outlook 2022 (NEW Live Video Webinar)

FDA Releases Draft Guidance on Essential Drug Delivery Outputs

Would I FIE to You? FDA’s First Interchangeable Exclusivity Determination Results in Expiration

Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

Stay Connected